FDA Licenses First-Ever Freeze-Dried Plasma Product in the U.S.
The FDA has licensed the first-ever freeze-dried plasma product for use in the U.S. This milestone advances trauma and resuscitation care by expanding blood product options available to healthcare providers and systems.
- Published date: 07-08-2026 10:03 AM
On July 29, 2026, the U.S. Food and Drug Administration (FDA) announced the licensing of the first freeze-dried plasma product for use in the United States. This approval marks a significant advancement in trauma care and resuscitation practices.
The introduction of freeze-dried plasma offers an innovative option for blood product availability, providing clinicians and health systems with a valuable tool in managing patients requiring plasma transfusions.
This development reflects ongoing efforts to enhance medical resources and improve outcomes in critical care situations. Healthcare professionals are encouraged to consider the implications of this new product in their clinical protocols.
The FDA has licensed the first-ever freeze-dried plasma product for use in the U.S. This milestone advances trauma and resuscitation care by expanding blood product options available to healthcare providers and systems.